U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07511972) titled 'Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies' on March 30.
Brief Summary: Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study Start Date: Nov. 14, 2023
Study Type: INTERVENTIONAL
Condition:
CRC
Intervention:
DRUG: NGM707 plus pembrolizumab
Drug: NGM707
NGM707 will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
Drug: pembrolizumab
Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
Recruitment Status: WITHDRAWN
Sponsor: NGM Biopharmaceuticals, Inc
Published...